◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PRTA

Prothena Corporation plc (PRTA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Prothena Corporation plc (PRTA) operates in the Biotechnology industry and is headquartered in Dublin, Ireland with about 67 employees. Its market capitalization is roughly $453 million. In the fiscal year ended 2025-12-31, PRTA reported $10M in revenue and ($244M) in net income.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.

Interactive charts & full statements → Open the PRTA valuation workbench →

PRTA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$10M$135M$91M$54M
Operating Income (EBIT)($185M)($155M)($191M)($132M)
Net Income($244M)($122M)($147M)($117M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$51M$0M$2M$4M$3M
Operating Income (EBIT)$26M($27M)($40M)($52M)($66M)
Net Income$33M($22M)($36M)($126M)($60M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PRTA Free Cash Flow History

PRTA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$327M$547M$696M$758M
Total Liabilities$46M$60M$135M$136M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRTA viewer.

Other Companies in Biotechnology

← PRSUAll stocksPRTH →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.